mRNA vaccine development for cholangiocarcinoma: a precise pipeline

Cholangiocarcinoma (CHOL) is one of the most aggressive tumors worldwide and cannot be effectively treated by conventional and novel treatments, including immune checkpoint blockade therapy. The mRNA vaccine-based immunotherapeutic strategy has attracted much attention for various diseases, however, its application in CHOL is limited due to the thoughtlessness in the integration of vaccine design and patient selection. A recent study established an integrated path for identifying potent CHOL antigens for mRNA vaccine development and a precise stratification for identifying CHOL patients who can benefit from the mRNA vaccines. In spite of a promising prospect, further investigations should identify immunogenic antigens and onco-immunological characteristics of CHOL to guide the clinical application of CHOL mRNA vaccines in the future.

Automated summary

Cholangiocarcinoma is a highly aggressive tumor that currently lacks effective treatment options. A recent study has proposed an immunotherapeutic strategy using mRNA vaccines, with a focus on selecting suitable patients and identifying potent antigens. However, further research is needed to better understand the immunogenic antigens and onco-immunological characteristics of cholangiocarcinoma for future clinical applications.